川芎平喘合剂防治支气管哮喘的临床及实验研究

Clinical and Experimental Study on Ligusticum wallichii Mixture in preventing and Treating Bronchial Asthma

川芎平喘合剂是我们长期用于治疗支气管哮喘的经验方，豚鼠过敏性哮喘模型的实验研究证实，其能明显拮抗由组胺和乙酰胆碱所介导的支气管平滑肌痉挛，降低哮喘的发生率及死亡率。在此基础上，扩大临床观察样本，川芎平喘合剂组１００例，对照组５０例。结果表明，川芎平喘合剂能明显提高１秒钟用力呼气容积占用力肺活量比值（ＦＥＶ１％）和降低血浆血栓素Ｂ２（ＴＸＢ２）值，总有效率为９２％，明显优于对照组（Ｐ＜０．０５），提示本合剂具有拮抗ＴＸＢ２的合成和释放，松弛平滑肌和改善肺功能的作用。

To investigate the significance of Ligusticum wallichii Mixture(LWM) and its possible therapeutical mechanism in bronchial asthma, clinical and experimental studies were carried out.Results: LWM inhibited bronchospasm induced by histamine and acetylcholine in guinea pigs; the plasma level of TXB2 was decreased remarkably and the incubation period from antigen inhalation to asthma attack could be delayed by LWM; the incidence of asthma and its mortality were reduced in guinea pigs, compared with control, P<0.01.In addition, the prolonged period of induced asthma attack was negatively correlated to the plasma level of TXB2 in guinea pigs(P<0.01).It was observed that the plasm level of TXB2 was decreased, the forced expiratory volume in 1 sec(FEV1%) was elevated significantly in asthmatic patients after they were treated by LWM.Moreover,the total effective rate was significantly better than that in the control(92%:62%).It indicated that: (1)The effects of airway allergic inflammation(AAI) might be the important pathological basis for the bronchial asthma,(2) TXA2 might be an important inflammatory mediator in asthma which could be taken as an useful biochemical parameter for evaluating clinical effects, (3) LWM could relax tracheal smooth muscle, improve pulmonary function, inhibit the synthesis and release of TXA2 with no side effects.